Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion
L Amini, SK Silbert, SL Maude, LJ Nastoupil… - Nature Reviews …, 2022 - nature.com
Chimeric antigen receptor (CAR) T cells have emerged as a potent therapeutic approach for
patients with certain haematological cancers, with multiple CAR T cell products currently …
patients with certain haematological cancers, with multiple CAR T cell products currently …
From bench to bedside: the history and progress of CAR T cell therapy
Chimeric antigen receptor (CAR) T cell therapy represents a major breakthrough in cancer
care since the approval of tisagenlecleucel by the Food and Drug Administration in 2017 for …
care since the approval of tisagenlecleucel by the Food and Drug Administration in 2017 for …
Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy
A paradigm shift has recently occurred in the field of cancer therapeutics. Traditional
anticancer agents, such as chemotherapy, radiotherapy and small-molecule drugs targeting …
anticancer agents, such as chemotherapy, radiotherapy and small-molecule drugs targeting …
Recent advances and discoveries in the mechanisms and functions of CAR T cells
This Review discusses the major advances and changes made over the past 3 years to our
understanding of chimeric antigen receptor (CAR) T cell efficacy and safety. Recently, the …
understanding of chimeric antigen receptor (CAR) T cell efficacy and safety. Recently, the …
[HTML][HTML] Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow …
Background Several commercial and academic autologous chimeric antigen receptor T-cell
(CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B …
(CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B …
Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes
The description of a so-called cytokine storm in patients with COVID-19 has prompted
consideration of anti-cytokine therapies, particularly interleukin-6 antagonists. However …
consideration of anti-cytokine therapies, particularly interleukin-6 antagonists. However …
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Background Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, chimeric
antigen receptor (CAR) T-cell product. We aimed to assess the activity and safety of liso-cel …
antigen receptor (CAR) T-cell product. We aimed to assess the activity and safety of liso-cel …
CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma
Hematotoxicity represents a frequent chimeric antigen receptor (CAR) T-cell–related
adverse event and remains poorly understood. In this multicenter analysis, we studied …
adverse event and remains poorly understood. In this multicenter analysis, we studied …
A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains
KM Cappell, JN Kochenderfer - Nature reviews Clinical oncology, 2021 - nature.com
Chimeric antigen receptors (CARs) are engineered proteins designed to target T cells to
cancer cells. To effectively activate the T cells in which they are expressed, CARs must …
cancer cells. To effectively activate the T cells in which they are expressed, CARs must …
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas
Autologous chimeric antigen receptor (CAR) T cell therapies targeting CD19 have high
efficacy in large B cell lymphomas (LBCLs), but long-term remissions are observed in less …
efficacy in large B cell lymphomas (LBCLs), but long-term remissions are observed in less …